Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IGlarLixi
Status:
Completed
Trial end date:
2020-09-30
Target enrollment:
Participant gender:
Summary
The purpose of the study is to determine whether in patients with early type 2 diabetes, a
short-term intensive metabolic intervention comprising iGlarLixi, metformin, and lifestyle
approaches will be superior to standard diabetes therapy in achieving sustained diabetes
remission.